The average cost of each cycle in light of Sanofi’s discount is “commercial in confidence”, says NICE, which said that it had changed its position in light of the new price as well as additional ...

Crohn’s disease patients can now get routine access to treatment with Takeda’s biologic Entyvio on the National Health Service in England and Wales after a full green light from cost regulators ...

NICE has given a green light for use of MSD’s Keytruda on the NHS to treat some patients with melanoma, with funding to come from the Cancer Drugs Fund. NICE has given a green light for use of MSD’s ...

NICE has given the green light via the Cancer Drugs Fund (CDF), which means Imfinzi must prove its value further before gaining full recommendation. AstraZeneca says it expects around 300 patients ...

Dabrafenib in combination with trametinib – both of which are made by Novartis – is being recommended by NICE in final draft guidance for treating BRAF V600E mutation-positive glioma. Gliomas are the ...

National Institute for Clinical Excellence (NICE) gives green light for pemigatinib (Pemazyre ®), the first targeted therapy for those with the ‘Cinderella’ cancer, cholangiocarcinoma AMMF, the UK’s ...

New guidance published today (24 October) by the National Institute for Health and Care Excellence (NICE) commits the NHS to funding the drug denosumab (XGEVA, Amgen) for cancer patients whose disease ...

The National Institute for Health and Care Excellence (NICE) declined coverage for Kisunla in a draft guidance, deeming it too costly for the “relatively small benefit it provides,” the ...